Cyclodialysis cleft repair: A multi-centred, retrospective case series.


Journal

Clinical & experimental ophthalmology
ISSN: 1442-9071
Titre abrégé: Clin Exp Ophthalmol
Pays: Australia
ID NLM: 100896531

Informations de publication

Date de publication:
03 2019
Historique:
received: 16 02 2018
revised: 01 08 2018
accepted: 19 08 2018
pubmed: 24 8 2018
medline: 11 4 2020
entrez: 24 8 2018
Statut: ppublish

Résumé

There is a paucity of evidence analysing the treatment of cyclodialysis clefts. We describe outcomes following the treatment of this rare condition at six centres internationally. Retrospective case series. Thirty-six patients with a cyclodialysis cleft from 2003 to 2017 were recruited. Clefts were treated with cycloplegic agents, laser therapy and/or surgery. Postoperative best recorded visual acuity (BRVA), intraocular pressure (IOP) and the rate of cleft closure. The mean age was 45 ± 17 years and 29 (80.6%) patients were male. One eye (2.8%) received only medical therapy, 5 (13.9%) received laser, 14 (38.9%) underwent surgery after laser failure and 16 (44.4%) eyes received exclusively surgery. Over 80% of eyes had a BRVA improvement of more than two lines. Closure was attained in 30 eyes (93.8%; n = 32), with postoperative stabilized IOP ≥ 12 mmHg in 29 eyes (80.6%; n = 36) and postoperative BRVA ≤20/50 in 20 eyes (58.8%; n = 34). Improved postoperative BRVA was related to better preoperative BRVA (P = 0.006) and preoperative IOP ≥ 4 mmHg (P = 0.03). There was no significant difference between treatment approach for IOP ≥ 12 mmHg (P = 0.85) or postoperative BRVA ≤20/50 (P = 0.80). Only two eyes at last follow-up required IOP lowering medication. There was a high closure rate with most eyes eventually requiring surgery. Clinically significant improvements in BRVA were found in most eyes. Improved postoperative BRVA was significantly related to better preoperative BRVA and IOP.

Sections du résumé

IMPORTANCE
There is a paucity of evidence analysing the treatment of cyclodialysis clefts.
BACKGROUND
We describe outcomes following the treatment of this rare condition at six centres internationally.
DESIGN
Retrospective case series.
PARTICIPANTS
Thirty-six patients with a cyclodialysis cleft from 2003 to 2017 were recruited.
METHODS
Clefts were treated with cycloplegic agents, laser therapy and/or surgery.
MAIN OUTCOME MEASURES
Postoperative best recorded visual acuity (BRVA), intraocular pressure (IOP) and the rate of cleft closure.
RESULTS
The mean age was 45 ± 17 years and 29 (80.6%) patients were male. One eye (2.8%) received only medical therapy, 5 (13.9%) received laser, 14 (38.9%) underwent surgery after laser failure and 16 (44.4%) eyes received exclusively surgery. Over 80% of eyes had a BRVA improvement of more than two lines. Closure was attained in 30 eyes (93.8%; n = 32), with postoperative stabilized IOP ≥ 12 mmHg in 29 eyes (80.6%; n = 36) and postoperative BRVA ≤20/50 in 20 eyes (58.8%; n = 34). Improved postoperative BRVA was related to better preoperative BRVA (P = 0.006) and preoperative IOP ≥ 4 mmHg (P = 0.03). There was no significant difference between treatment approach for IOP ≥ 12 mmHg (P = 0.85) or postoperative BRVA ≤20/50 (P = 0.80). Only two eyes at last follow-up required IOP lowering medication.
CONCLUSIONS AND RELEVANCE
There was a high closure rate with most eyes eventually requiring surgery. Clinically significant improvements in BRVA were found in most eyes. Improved postoperative BRVA was significantly related to better preoperative BRVA and IOP.

Identifiants

pubmed: 30136340
doi: 10.1111/ceo.13378
doi:

Substances chimiques

Mydriatics 0

Types de publication

Case Reports Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

201-211

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2018 Royal Australian and New Zealand College of Ophthalmologists.

Auteurs

Marko Popovic (M)

Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Shakeel Shareef (S)

Flaum Eye Institute, University of Rochester School of Medicine and Dentistry, Rochester, New York.

Juan J Mura (JJ)

Centro de la Visión, Hospital Del Salvador, Universidad de Chile, Santiago, Chile.

Felipe Valenzuela (F)

Clinica Universidad de Los Andes, Santiago, Chile.

Julio González Martín-Moro (J)

Department of Ophthalmology, Hospital Universitario del Henares, Madrid, Spain.

Matthew B Schlenker (MB)

Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.

Keith Barton (K)

Glaucoma Service, Moorfields Eye Hospital, London, UK.

Francisco Muñoz-Negrete (F)

Department of Ophthalmology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.

Mohammad Reza Razeghinejad (MR)

Glaucoma Service, Wills Eye Institute, Philadelphia, Pennsylvania.
Poostchi Eye Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Iqbal Ike K Ahmed (IIK)

Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH